Discovery of N-(Indazol-3-yl)piperidine-4-carboxylic Acids as RORγt Allosteric Inhibitors for Autoimmune Diseases

H Zhang, BT Lapointe, N Anthony… - ACS Medicinal …, 2020 - ACS Publications
The clinical success of anti-IL-17 monoclonal antibodies (ie, Cosentyx and Taltz) has
validated Th17 pathway modulation for the treatment of autoimmune diseases. The nuclear …
被引用次数：20 相关文章

[引用][C] Discovery of N-(Indazol-3-yl) piperidine-4-carboxylic Acids as ROR [gamma] t Allosteric Inhibitors for

H Zhang, BT Lapointe, N Anthony, R Azevedo… - ACS Med. Chem …, 2020 - osti.gov
[HTML] nih.gov

[HTML][HTML] Discovery of N-(Indazol-3-yl) piperidine-4-carboxylic Acids as RORγt Allosteric Inhibitors for Autoimmune Diseases

H Zhang, BT Lapointe, N Anthony… - ACS Medicinal …, 2020 - ncbi.nlm.nih.gov
The clinical success of anti-IL-17 monoclonal antibodies (ie, Cosentyx and Taltz) has
validated Th17 pathway modulation for the treatment of autoimmune diseases. The nuclear …

Discovery of N-(Indazol-3-yl) piperidine-4-carboxylic Acids as RORγt Allosteric Inhibitors for Autoimmune Diseases

H Zhang, BT Lapointe, N Anthony… - ACS medicinal …, 2020 - pubmed.ncbi.nlm.nih.gov
The clinical success of anti-IL-17 monoclonal antibodies (ie, Cosentyx and Taltz) has
validated Th17 pathway modulation for the treatment of autoimmune diseases. The nuclear …

Discovery of N-(Indazol-3-yl)piperidine-4-carboxylic Acids as RORγt Allosteric Inhibitors for Autoimmune Diseases.

H Zhang, BT Lapointe, N Anthony… - ACS Medicinal …, 2020 - europepmc.org
The clinical success of anti-IL-17 monoclonal antibodies (ie, Cosentyx and Taltz) has
validated Th17 pathway modulation for the treatment of autoimmune diseases. The nuclear …

Discovery of N-(Indazol-3-yl) piperidine-4-carboxylic Acids as RORγt Allosteric Inhibitors for Autoimmune Diseases

H Zhang, BT Lapointe, N Anthony, R Azevedo… - 2020 - scholarlypublications …
The clinical success of anti-IL-17 monoclonal antibodies (ie, Cosentyx and Taltz) has
validated Th17 pathway modulation for the treatment of autoimmune diseases. The nuclear …

Discovery of N-(Indazol-3-yl)piperidine-4-carboxylic Acids as RORγt Allosteric Inhibitors for Autoimmune Diseases.

H Zhang, BT Lapointe, N Anthony… - ACS Medicinal …, 2020 - europepmc.org
The clinical success of anti-IL-17 monoclonal antibodies (ie, Cosentyx and Taltz) has
validated Th17 pathway modulation for the treatment of autoimmune diseases. The nuclear …